BioMarin aims to scoop up rare disease drugs as orphan field sizzles

With the rare disease drug field as crowded as ever, BioMarin Pharmaceutical ($BMRN) is in the market to snap up smaller developers of the treatments to build on the company's established position in the market, CEO Jean-Jacques Bienaime told Bloomberg.

BioMarin has a track record of scooping up small rare disease players on the cheap. For example, it spent $22 million upfront for ZyStor in a deal that could be worth up to $115 million. Through that deal, BioMarin acquired ZyStor's Pompe disease drug (now called BMN-701). Bienaime told Bloomberg that the Pompe drug is due to enter Phase III in 2013, and it could compete with Genzyme's lucrative therapies for the rare ailment.

BioMarin, which already markets three drugs for rare diseases, has seen the number of players surge in recent years. Big Pharma has gotten in on the action, realizing the short time frames for developing orphan disease drugs, the high price tags of $200,000 or more for the therapies and other perks translate into a significant business opportunity. And the competition for gaining rights to assets in the rare disease field is fierce, with Shire, Pfizer ($PFE), Sanofi ($SNY), GlaxoSmithKline ($GSK) and others showing a willingness to bid for them.

Biotech companies are aiming to capitalize on the drugmakers' big appetites for rare disease drugs. For example, Alnylam ($ALNY) last week revealed that its RNA-interference drug for the rare disorder transthyretin-mediated amyloidosis is now one of its two lead programs. The company is attempting to translate its gene-silencing tech into commercially viable drugs.

While facing growing competition for licensing or buying rare disease drugs, BioMarin isn't relying exclusively on external sources for new products. The California biotech has 5 clinical programs under way, and its lead experimental candidate, called GALNS, is due to generate late-stage clinical date this year in patients with the genetic bone disease Morquio A syndrome, Bloomberg reports.

- get more in the Bloomberg article

Special Report: BioMarin Pharmaceutical - Biotech's Biggest Spenders 2011

Related Articles:
BioMarin perfects the popular rare disease drug model
BioMarin snares orphan drug upstart in $115M buyout

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.